Literature DB >> 23891336

Incidence of scleritis and episcleritis: results from the Pacific Ocular Inflammation Study.

Gelareh Homayounfar1, Natalie Nardone, Durga S Borkar, Vivien M Tham, Travis C Porco, Wayne T A Enanoria, John V Parker, Aleli C Vinoya, Aileen Uchida, Nisha R Acharya.   

Abstract

PURPOSE: To ascertain the incidence of scleritis and episcleritis in a Hawaiian population and describe variations by age, sex, and race.
DESIGN: Retrospective, population-based cohort study.
METHODS: All electronic medical records for enrollees in Kaiser Permanente Hawaii (n = 217,061) from January 1, 2006 to December 31, 2007 were searched for International Classification of Diseases, 9th Edition (ICD-9) codes associated with ocular inflammation. Chart review was conducted to verify a clinical diagnosis of scleritis or episcleritis. Confirmed cases were used to calculate incidence rates per 100,000 person-years. Ninety-five percent confidence intervals (CI) were calculated for each incidence rate, including age-, sex-, and race-specific rates, using bias-corrected Poisson regression. To assess for confounding, a multivariate analysis adjusting for age, sex, and race was also performed.
RESULTS: Of 217,061 eligible patients, 17 incident scleritis cases and 93 incident episcleritis cases were confirmed. The overall incidence rates of scleritis and episcleritis were 4.1 (95% CI: 2.6-6.6) and 21.7 (95% CI: 17.7-26.5) cases per 100,000 person-years, respectively. Women were overrepresented among scleritis patients (P = .049). Pacific Islanders were the most underrepresented racial group among cases of scleritis and episcleritis (P = .006, P = .001). Blacks had the highest incidence of scleritis (P = .004).
CONCLUSIONS: These results provide a population-based estimate of the incidence of scleritis and episcleritis in a diverse population and highlight differences in patients' demographic characteristics. Differences in incidence by sex and race raise questions about genetic and environmental influences on the development of these conditions.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23891336      PMCID: PMC3852161          DOI: 10.1016/j.ajo.2013.05.026

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  31 in total

Review 1.  Scleritis.

Authors:  Narciss Okhravi; Bola Odufuwa; Peter McCluskey; Susan Lightman
Journal:  Surv Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 6.048

Review 2.  Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization.

Authors:  B A Rybicki; M Major; J Popovich; M J Maliarik; M C Iannuzzi
Journal:  Am J Epidemiol       Date:  1997-02-01       Impact factor: 4.897

3.  Episcleritis and scleritis. Association with connective tissue disease.

Authors:  A J Lyne; D A Pitkeathley
Journal:  Arch Ophthalmol       Date:  1968-08

4.  The epidemiology of polymyositis.

Authors:  T A Medsger; W N Dawson; A T Masi
Journal:  Am J Med       Date:  1970-06       Impact factor: 4.965

5.  Severity of episcleritis and systemic disease association.

Authors:  E K Akpek; H S Uy; W Christen; C Gurdal; C S Foster
Journal:  Ophthalmology       Date:  1999-04       Impact factor: 12.079

6.  Scleritis and episcleritis.

Authors:  P G Watson; S S Hayreh
Journal:  Br J Ophthalmol       Date:  1976-03       Impact factor: 4.638

7.  Scleritis and associated disease.

Authors:  S M Lachmann; B L Hazleman; P G Watson
Journal:  Br Med J       Date:  1978-01-14

8.  Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression.

Authors:  C S Foster; S L Forstot; L A Wilson
Journal:  Ophthalmology       Date:  1984-10       Impact factor: 12.079

9.  Severity of scleritis and episcleritis.

Authors:  M Sainz de la Maza; N S Jabbur; C S Foster
Journal:  Ophthalmology       Date:  1994-02       Impact factor: 12.079

10.  Ocular presentation of polyarteritis nodosa. Clinical course and management with steroid and cytotoxic therapy.

Authors:  Y A Akova; N S Jabbur; C S Foster
Journal:  Ophthalmology       Date:  1993-12       Impact factor: 12.079

View more
  4 in total

1.  Clinical patterns and risk factors in scleritis: a multicentric study in Colombia.

Authors:  Alejandra de-la-Torre; Mariana Cabrera-Pérez; Claudia Durán; Sandra García; Miguel Cuevas; Néstor Carreño; Carlos M Rangel; Diana Isabel Pachón-Suárez; María Alejandra Martínez-Ceballos; María Elisa Mejía; Alejandra Gómez-Rocha; Camilo Andrés Gómez-Durán; Yanny Pérez; Juliana Reyes-Guanes; Carlos Cifuentes-González; William Rojas-Carabali
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-07-07       Impact factor: 3.117

Review 2.  Noninfectious Autoimmune Scleritis: Recognition, Systemic Associations, and Therapy.

Authors:  Alana Nevares; Robert Raut; Bonita Libman; Rula Hajj-Ali
Journal:  Curr Rheumatol Rep       Date:  2020-03-26       Impact factor: 4.592

Review 3.  Scleritis: Differentiating infectious from non-infectious entities.

Authors:  Somasheila I Murthy; Swapnali Sabhapandit; S Balamurugan; Pranesh Subramaniam; Maite Sainz-de-la-Maza; Manisha Agarwal; Carlos Parvesio
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

4.  Characteristics and Outcomes of Patients with Scleritis in the IRIS® Registry (Intelligent Research in Sight) Database.

Authors:  Karen R Armbrust; Laura J Kopplin
Journal:  Ophthalmol Sci       Date:  2022-06-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.